logo-loader
AIM:AVCT

Avacta Group PLC

Receive alerts
Market:
AIM
Market Cap:
£37.85 m
Price
21.50 GBX
Change
0.00%
52 weeks high
38.40
52 weeks low
12.62

In brief

At Avacta we have developed Affimer technology, an engineered alternative to antibodies. Based on a small protein, Affimer technology can be quickly developed to bind with high specificity and affinity to a wide range of targets.

Affimer proteins can be developed as therapeutic molecules and can be used in a wide range of other life sciences applications in research and diagnostics.